These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 31483070)

  • 1. Combination therapy in overactive bladder-untapped research opportunities: A systematic review of the literature.
    Kasman A; Stave C; Elliott CS
    Neurourol Urodyn; 2019 Nov; 38(8):2083-2092. PubMed ID: 31483070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticholinergic drugs versus non-drug active therapies for non-neurogenic overactive bladder syndrome in adults.
    Rai BP; Cody JD; Alhasso A; Stewart L
    Cochrane Database Syst Rev; 2012 Dec; 12(12):CD003193. PubMed ID: 23235594
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Shifts in patient preference of third-line overactive bladder therapy after introduction of the implantable tibial nerve stimulator.
    Kapur A; Aalami Harandi A; Hartman-Kenzler J; Kim J
    Neurourol Urodyn; 2024 Apr; 43(4):959-966. PubMed ID: 38390786
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults.
    Alhasso AA; McKinlay J; Patrick K; Stewart L
    Cochrane Database Syst Rev; 2006 Oct; (4):CD003193. PubMed ID: 17054163
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The management of overactive bladder: percutaneous tibial nerve stimulation, sacral nerve stimulation, or botulinum toxin?
    Tubaro A; Puccini F; De Nunzio C
    Curr Opin Urol; 2015 Jul; 25(4):305-10. PubMed ID: 26049873
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Overactive Bladder-Wet Syndrome on Female Sexual Function: A Systematic Review and Meta-Analysis.
    Balzarro M; Rubilotta E; Mancini V; Trabacchin N; Oppezzi L; Li Marzi V; Fusco F; Serati M
    Sex Med Rev; 2019 Oct; 7(4):565-574. PubMed ID: 31326358
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of OAB in those over age 65.
    Natalin R; Lorenzetti F; Dambros M
    Curr Urol Rep; 2013 Oct; 14(5):379-85. PubMed ID: 23922134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Percutaneous tibial nerve stimulation versus tolterodine for overactive bladder in women: a randomised controlled trial.
    Preyer O; Umek W; Laml T; Bjelic-Radisic V; Gabriel B; Mittlboeck M; Hanzal E
    Eur J Obstet Gynecol Reprod Biol; 2015 Aug; 191():51-6. PubMed ID: 26073262
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatments for overactive bladder: focus on pharmacotherapy.
    Geoffrion R;
    J Obstet Gynaecol Can; 2012 Nov; 34(11):1092-1101. PubMed ID: 23231848
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of factors that influence patient preference of third-line therapy for overactive bladder.
    Kapur A; Harandi AA; Cohen T; Ruan H; Dabrowski C; Anderson R; Hwang K; Lee E; Weissbart S; Kim J
    Neurourol Urodyn; 2022 Nov; 41(8):1906-1913. PubMed ID: 36104866
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overactive Bladder.
    White N; Iglesia CB
    Obstet Gynecol Clin North Am; 2016 Mar; 43(1):59-68. PubMed ID: 26880508
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous tibial nerve stimulation versus electrical stimulation with pelvic floor muscle training for overactive bladder syndrome in women: results of a randomized controlled study.
    Scaldazza CV; Morosetti C; Giampieretti R; Lorenzetti R; Baroni M
    Int Braz J Urol; 2017; 43(1):121-126. PubMed ID: 28124534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Botulinum toxin injections for adults with overactive bladder syndrome.
    Duthie JB; Vincent M; Herbison GP; Wilson DI; Wilson D
    Cochrane Database Syst Rev; 2011 Dec; (12):CD005493. PubMed ID: 22161392
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathophysiology of refractory overactive bladder.
    Chen LC; Kuo HC
    Low Urin Tract Symptoms; 2019 Sep; 11(4):177-181. PubMed ID: 30900373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment patterns and costs among patients with OAB treated with combination oral therapy, sacral nerve stimulation, percutaneous tibial nerve stimulation, or onabotulinumtoxinA in the United States.
    Kraus SR; Shiozawa A; Szabo SM; Qian C; Rogula B; Hairston J
    Neurourol Urodyn; 2020 Nov; 39(8):2206-2222. PubMed ID: 32827230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Behavioral therapies for overactive bladder: making sense of the evidence.
    Milne JL
    J Wound Ostomy Continence Nurs; 2008; 35(1):93-101; quiz 102-3. PubMed ID: 18199944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Outcomes of different protocols of pelvic floor physical therapy and anti-cholinergics in women with wet over-active bladder: A 4-year follow-up.
    Azuri J; Kafri R; Ziv-Baran T; Stav K
    Neurourol Urodyn; 2017 Mar; 36(3):755-758. PubMed ID: 27080326
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-center randomized controlled trial of cognitive treatment, placebo, oxybutynin, bladder training, and pelvic floor training in children with functional urinary incontinence.
    van Gool JD; de Jong TP; Winkler-Seinstra P; Tamminen-Möbius T; Lax H; Hirche H; Nijman RJ; Hjälmås K; Jodal U; Bachmann H; Hoebeke P; Walle JV; Misselwitz J; John U; Bael A;
    Neurourol Urodyn; 2014 Jun; 33(5):482-7. PubMed ID: 23775924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sacral neuromodulation for refractory overactive bladder after prior intravesical onabotulinumtoxinA treatment.
    Hoag N; Plagakis S; Pillay S; Edwards AW; Gani J
    Neurourol Urodyn; 2017 Jun; 36(5):1377-1381. PubMed ID: 27612039
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What uro-gynecologists should know about sacral neuromodulation (SNM) for the treatment of refractory overactive bladder.
    Oelke M; Addali M; Reisenauer C
    Arch Gynecol Obstet; 2019 May; 299(5):1243-1252. PubMed ID: 30941558
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.